Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(166 productos)
- Bcr-Abl(117 productos)
- EGFR(561 productos)
- FAK(72 productos)
- FLT(88 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(243 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(51 productos)
- VDA(2 productos)
- VEGFR(238 productos)
Mostrar 6 subcategorías más
Se han encontrado 2272 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Fórmula:C18H15N3O2Forma y color:SolidPeso molecular:305.331HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23VEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Fórmula:C20H21N3O2Forma y color:SolidPeso molecular:335.4E7090 succinate
CAS:E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.Fórmula:C76H92N10O24Forma y color:SolidPeso molecular:1529.60Antiallergic agent-1
Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.Fórmula:C27H19F6N5OForma y color:SolidPeso molecular:543.46DHFR-IN-4
CAS:DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer.Fórmula:C18H21N5O2SPureza:99.41%Forma y color:SolidPeso molecular:371.46TTT 3002
CAS:TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.50JAK2 JH2 binder-1
CAS:JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Fórmula:C33H28N6O3SForma y color:SolidPeso molecular:588.68ALK-IN-31
CAS:ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Fórmula:C30H33N5O2SForma y color:SolidPeso molecular:527.68RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Fórmula:C29H37Cl2N7O4Forma y color:SolidPeso molecular:618.55Tyk2-IN-10
CAS:Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Fórmula:C25H27N5O3Forma y color:SolidPeso molecular:445.51BMS-066
CAS:BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Fórmula:C19H21N7O2Pureza:98%Forma y color:SolidPeso molecular:379.42EGFR-IN-62
EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.Fórmula:C30H33N9O2Forma y color:SolidPeso molecular:551.64PF-06463922 acetate
CAS:PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Fórmula:C23H23FN6O4Forma y color:SolidPeso molecular:466.46FGFR1 inhibitor-6
FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.Fórmula:C27H19N5O4S2Forma y color:SolidPeso molecular:541.6Tuspetinib dihydrochloride
CAS:Tuspetinib (HM43239) dihydrochloride is a selective FLT3 inhibitor with oral bioactivity, exhibiting IC50 values of 1.1 nM for FLT3 wild type, 1.8 nM for FLT3ITD mutant type, and 1.0 nM for FLT3D835Y mutant type. As a reversible type I inhibitor, it directly suppresses FLT3 kinase activity and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib dihydrochloride inhibits the proliferation of leukemia cells and induces apoptosis (apoptosis).Fórmula:C29H35Cl3N6Forma y color:SolidPeso molecular:573.99VEGFR-2-IN-38
CAS:VEGFR-2-IN-38 (compound 3) acts as a potential inhibitor of the vascular endothelial growth factor receptor-2 [1].Fórmula:C17H12N4SForma y color:SolidPeso molecular:304.37(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Fórmula:C25H22N6O2Forma y color:SolidPeso molecular:438.48ALK-IN-23
ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.Fórmula:C26H29ClN8O3SForma y color:SolidPeso molecular:569.08BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Fórmula:C25H24F2N4O2Forma y color:SolidPeso molecular:450.48VEGFR-2-IN-52
CAS:VEGFR-2-IN-52 (compound 14d) serves as a powerful inhibitor of VEGFR-2, exhibiting an IC 50 of 191.1 nM. It effectively reduces the protein expression levels of p-VEGFR-2, MMP9, p-ERK1/2, and p-MEK1. In addition, VEGFR-2-IN-52 demonstrates cytotoxic properties by inducing apoptosis and arresting the cell cycle at the G0/G1 phase, and it enhances the levels of ROS.Fórmula:C20H25ClN4O2SForma y color:SolidPeso molecular:420.96FLT3-IN-32
CAS:FLT3-IN-32 is a potent FLT3 inhibitor with high selectivity, effectively suppressing FLT3 activating mutations and inducing apoptosis. It demonstrates good tolerance in non-tumor-bearing mice. In NOD/SCID mice loaded with MV4-11 cells, FLT3-IN-32 exhibits outstanding antitumor efficacy, significantly extending mouse survival. FLT3-IN-32 is applicable for acute myeloid leukemia research.Fórmula:C28H29N5O5Forma y color:SolidPeso molecular:515.56Pred17
Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.Fórmula:C27H22BN3OForma y color:SolidPeso molecular:415.297PPD-Q
CAS:7PPD-Q is a substituted p-phenylenediamine antioxidant derivative. It exhibits toxicity towards the bacterium V. fischeri (EC50= 14.9 mg/L).Fórmula:C19H24N2O2Forma y color:SolidPeso molecular:312.41D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Fórmula:C25H26Cl2FN7O3Forma y color:SolidPeso molecular:562.42ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Fórmula:C36H45N5O3Forma y color:SolidPeso molecular:595.77VEGFR-2-IN-14
VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Fórmula:C24H23N3O3SForma y color:SolidPeso molecular:433.52EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Fórmula:C31H30FN7OForma y color:SolidPeso molecular:535.61UNC9750
CAS:UNC9750 is an inhibitor of inositol phosphate multikinase (IPMK), with IC50 values of 31.6 nM for IPMK and 374 nM for IP6K2. It effectively suppresses the accumulation of InsP5, a direct product of IPMK kinase activity, without affecting InsP6 or InsP7 levels. Additionally, UNC9750 inhibits over 75% of the activity of four kinases: DAPK1, DYRK1B, PDGFR, and KDR. This compound is applicable in glioblastoma research.Fórmula:C23H24N6OForma y color:SolidPeso molecular:400.48YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65mG2N001
CAS:mG2N001, a negative allosteric modulator (NAM) of the metabotropic glutamate receptor mGluR2, has an IC50 of 93 nM and binds to mGluR2 as an antagonist with a Ki of 63 nM. This compound is microparticle- and plasma-stable, and its radioisotope [11C] mG2N001 can be utilized in PET imaging. [11C] mG2N001 exhibits good brain heterogeneity and penetration, selectively accumulating in mGluR2-rich regions to produce high-contrast brain images [1].Fórmula:C18H19FN2O3Forma y color:SolidPeso molecular:330.35Londamocitinib
CAS:Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Fórmula:C28H31F2N7O4SPureza:98.64% - 99.56%Forma y color:SolidPeso molecular:599.65Ref: TM-T11706
1mg170,00€5mg416,00€10mg567,00€25mg858,00€50mg1.108,00€100mg1.485,00€1mL*10mM (DMSO)537,00€EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Fórmula:C12H14N4OS2Forma y color:SolidPeso molecular:294.4HPK1-IN-61
CAS:HPK1-IN-61 (Compound 1) serves as an inhibitor of hematopoietic progenitor kinase 1 (HPK1) with a Ki of 0.4 nM, and also inhibits Abl with an IC50 of less than 0.51 nM. Additionally, HPK1-IN-61 displays inhibitory activity against LCK, with an IC50 of 24 nM.Fórmula:C23H22N4O2Forma y color:SolidPeso molecular:386.45WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Fórmula:C33H45BrN8O5SForma y color:SolidPeso molecular:745.73CEP-7055
CAS:CEP-18770: oral proteasome inhibitor; blocks NF-kappaB; may cause cancer cell apoptosis; less toxic than bortezomib in normal cells.Fórmula:C32H35N3O4Forma y color:SolidPeso molecular:525.64TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Fórmula:C40H47N11O5Forma y color:SolidPeso molecular:761.87HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Fórmula:C12H22NO11PForma y color:SolidPeso molecular:387.28Multi-kinase inhibitor 4
CAS:Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.Fórmula:C25H24N6O2Forma y color:SolidPeso molecular:440.50VVD-118313
CAS:VVD-118313 (5a) is a potent JAK1 inhibitor targeting allosteric cysteine, blocking cytokine signaling for cancer research.Fórmula:C19H22Cl2N2O3SForma y color:SolidPeso molecular:429.36YSY01A
CAS:YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.Fórmula:C29H38BN5O5Forma y color:SolidPeso molecular:547.45FAK-IN-23
CAS:FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).Fórmula:C32H38F3N5O8Forma y color:SolidPeso molecular:677.668HSN748
CAS:HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.Fórmula:C27H24F3N7OForma y color:SolidPeso molecular:519.521SILA-123
CAS:SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.Fórmula:C24H25N5O2Forma y color:SolidPeso molecular:415.49Multi-kinase inhibitor 3
CAS:Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52Ersentilide
CAS:Ersentilide, a benzamide derivative, functions as both a β1-adrenergic receptor antagonist and an Ikr blocker. It has demonstrated efficacy in animal models of cardiac arrhythmias.Fórmula:C21H26N4O5SForma y color:SolidPeso molecular:446.52CLM3
CAS:CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.Fórmula:C21H21N5Forma y color:SolidPeso molecular:343.43FLT3/ITD-IN-1
FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.Fórmula:C19H22N6O2Forma y color:SolidPeso molecular:366.42SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Fórmula:C27H26ClF4N5OForma y color:SolidPeso molecular:547.98FGFR4-IN-4
CAS:FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.Fórmula:C28H32Cl2N6O5Pureza:98%Forma y color:SolidPeso molecular:603.5NDI-034858
CAS:NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFórmula:C23H24N8O3Pureza:>99.99%Forma y color:SolidPeso molecular:460.49Vatalanib hydrochloride
CAS:Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Fórmula:C20H16Cl2N4Pureza:99.7%Forma y color:SolidPeso molecular:383.27JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Fórmula:C28H39N3O3Forma y color:SolidPeso molecular:465.63XMD-17-51 Trifluoroacetate
CAS:XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Fórmula:C23H25F3N8O3Pureza:99.65%Forma y color:SolidPeso molecular:518.49JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Fórmula:C26H33N7OPureza:99.54%Forma y color:SolidPeso molecular:459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Fórmula:C25H24N6O2Pureza:98%Forma y color:SolidPeso molecular:440.5PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Forma y color:Odour LiquidENMD-2076 tartrate
CAS:ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Fórmula:C25H31N7O6Forma y color:SolidPeso molecular:525.56TLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFórmula:C16H15N5Forma y color:Yellow SolidPeso molecular:277.331XMU-MP-3
CAS:XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Fórmula:C27H27F3N8OForma y color:SolidPeso molecular:536.563(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37Imbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Forma y color:Odour LiquidDihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Fórmula:C25H26N6O4Forma y color:SolidPeso molecular:474.521Nimotuzumab (powder)
CAS:Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Forma y color:LiquidHMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Forma y color:Odour LiquidDesidustat
CAS:Desidustat is an inhibitor of HIF hydroxylase.
Fórmula:C16H16N2O6Pureza:98%Forma y color:SolidPeso molecular:332.31Olmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFórmula:C26H26N6O2SPureza:99.14%Forma y color:SolidPeso molecular:486.59PF-03814735
CAS:PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Fórmula:C23H25F3N6O2Pureza:98%Forma y color:SolidPeso molecular:474.48Duligotuzumab
CAS:Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Pureza:95%Forma y color:LiquidRef: TM-T80604
Producto descatalogado3,3',4,4'-Tetrabromobiphenyl
CAS:Producto controladoApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Fórmula:C12H6Br4Forma y color:Off-White To Light BrownPeso molecular:469.79
